Meeting
2020 ASCO Virtual Scientific Program
ELLA01-1: A study to determine the utility of TP53 mutations as a prognostic biomarker in adenoid cystic carcinoma.
Authors
Robert Metcalf
The Christie NHS Foundation Trust, Manchester, United Kingdom
Robert Metcalf , Khaireah Mubarak , Becky Bola , Samuel Rack , David Morgan , Tracy Hussell , Andrew Wallace , Guy Betts , Kevin Joseph Harrington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6585)
DOI
10.1200/JCO.2020.38.15_suppl.6585
Abstract #
6585
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical outcomes of NOTCH pathway-activated adenoid cystic carcinoma with and without co-occurrent TP53 mutation.
First Author: Syeda Malaika Haider
Poster
2015 Gastrointestinal Cancers Symposium
Effect of TP53 mutation status on survival in the MAGIC trial.
First Author: Elizabeth Catherine Smyth
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
First Author: Nitzan Zohar
Poster
2023 ASCO Annual Meeting
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.
First Author: Alexander Peltzer